High-throughput simultaneous quantification of five azole anti-fungal agents and one active metabolite in human plasma using ultra-high-performance liquid chromatography coupled to tandem mass spectrometry

Tanaka, Ryota; Shiraiwa, Ken; Takano, Kuniko; Ogata, Masao; Honda, Shuhei; Yoshida, Natsumi; Okuhiro, Kazuki; Yoshida, Masaki; Narahara, Kumiko; Kai, Makoto; Tatsuta, Ryosuke

doi:10.1016/j.clinbiochem.2021.10.010

Cited by 7 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thirteen studies used LC‐MS/MS 42–54 . Four studies used HPLC‐MS/MS, 56–59 and seven studies used UHPLC‐MS/MS 60–66 . In addition, Reddy et al, 42 van der Elst et al 46 and Baietto et al 59 described the method to determine the concentration of posaconazole in dried blood spot (DBS) samples.…”

Section: What Is Known and Objectivementioning

confidence: 99%

“…Among the methods summarized in Table 1, twenty‐eight studies used protein precipitation, with acetonitrile selected as the precipitant in most of them 24,27,31–33,39,42–49,51–58,60,61,63–66 . Eight studies used liquid–liquid extraction, with dichloromethane and n‐hexane as the main extractants, 25,29,30,35,36,40,41,59 and solid phase extraction was used in five studies 26,28,34,62 . Most liquid chromatographic methods select acetonitrile as the organic phase and water or phosphate buffer as the aqueous phase, with a linear range from a minimum concentration of 0.05 mg/L to a maximum concentration of 16 mg/L.…”

Section: What Is Known and Objectivementioning

confidence: 99%

“…[42][43][44][45][46][47][48][49][50][51][52][53][54] Four studies used HPLC-MS/MS, [56][57][58][59] and seven studies used UHPLC-MS/MS. [60][61][62][63][64][65][66] In addition, Reddy et al, 42 van der Elst et al 46 and Baietto et al 59 described the method to determine the concentration of posaconazole in dried blood spot (DBS) samples.…”

Section: What Is Known and Objectivementioning

confidence: 99%

“…24,27,[31][32][33]39,[42][43][44][45][46][47][48][49][51][52][53][54][55][56][57][58]60,61,[63][64][65][66] Eight studies used liquid-liquid extraction, with dichloromethane and n-hexane as the main extractants, 25,29,30,35,36,40,41,59 and solid phase extraction was used in five studies. 26,28,34,62 Most liquid chromatographic methods select acetonitrile as the organic phase and water or phosphate buffer as the aqueous phase, with a linear range from a minimum concentration of 0.05 mg/L to a maximum concentration of 16 mg/L. Most LC-MS/MS methods select acetonitrile containing formic acid as the organic phase and ammonium formate or ammonium acetate buffer as the aqueous phase, with a minimum concentration of 5 ng/L and a maximum concentration of 20 mg/L for the linear range.…”

Section: What Is Known and Objectivementioning

confidence: 99%

See 3 more Smart Citations

Progress of triazole antifungal agent posaconazole in individualized therapy

Shu

Shi

Yang

et al. 2022

Clinical Pharmacy Therapeu

View full text Add to dashboard Cite

What is known and objective: Posaconazole is the second-generation triazole antifungal agent with widespread clinical application. Posaconazole exposure is influenced by various factors such as drug interactions, disease state and diet, resulting in a high interindividual variability in many patients and failure to ensure therapeutic efficacy. Therefore, it is necessary to conduct individualized therapy on posaconazole to ensure the efficacy and safety of treatment.Methods: Articles were identified through PubMed using the keywords such as "posaconazole," "therapeutic drug monitoring" and "Population pharmacokinetics" from 1 January 2001 to 30 April 2022. Results and discussion: In this paper, we review the individualized treatment studies of posaconazole from the three aspects of therapeutic drug monitoring, population pharmacokinetic study and Monte Carlo simulation to provide reference for in-depth individualized posaconazole dosing studies. What is new and conclusion: This review suggests that therapeutic drug monitoring should be performed in patients taking posaconazole to adjust the dosage and assess the efficacy and cost-effectiveness of posaconazole under different clinical conditions and different dosing regimens through Monte Carlo simulations. In the future, a more detailed delineation and comprehensive examination of posaconazole PPK for specific populations requires further study.

show abstract

Section: What Is Known and Objectivementioning

confidence: 99%

Section: What Is Known and Objectivementioning

confidence: 99%

Section: What Is Known and Objectivementioning

confidence: 99%

Section: What Is Known and Objectivementioning

confidence: 99%

See 2 more Smart Citations

Progress of triazole antifungal agent posaconazole in individualized therapy

Shu

Shi

Yang

et al. 2022

Clinical Pharmacy Therapeu

View full text Add to dashboard Cite

show abstract

“…Additionally, in other aspects, such as the standard range, LLOQ and run time, the methods used in this research are similar or superior to some other methods published recently. [18][19][20][21] Drug interactions can reduce the bioavailability of a particular medication, which can lead to treatment failure or increase the likelihood of side effects and even toxicity. There are currently no reports on the combined use of FLC and DHM drugs.…”

Section: Introductionmentioning

confidence: 99%

The Effect of Dihydromyricetin on the Pharmacokinetics of Fluconazole in Sprague-Dawley Rat Plasma, Based on High-Performance Liquid Chromatography–Tandem Mass Spectrometry

Liu,

Dong,

Guo

et al. 2023

DDDT

View full text Add to dashboard Cite

Background The synergistic effect of dihydromyricetin (DHM) and fluconazole (FLC) can improve the killing effect of FLC-resistant Candida albicans in vitro and in vivo. However, it is not clear whether DHM affects the pharmacokinetic characteristics of FLC. Methods In this study, 12 Sprague–Dawley (SD) rats were randomly divided into two groups as follows: (1) an FLC group in which rats were administered FLC only (42 mg/kg orally); (2) an FLC with the combined administration of DHM group, in which rats received an equivalent FLC dose immediately following the administration of DHM (100 mg/kg). Blood samples were collected from the ocular choroid vein of rats and converted into plasma. The concentrations of FLC in the rat plasma were then determined by high-performance liquid chromatography–tandem mass spectrometry (HPLC-MS/MS), and the related pharmacokinetic parameters were analysed. The initial mobile phase included 0.1% acetonitrile and water with gradient elution. Multiple reaction monitoring modes of m/z 307.2→220.1 for FLC, and m/z 237.1→194.2 for carbamazepine, were utilised to conduct quantitative analysis. Results The calibration curve of FLC in rat plasma demonstrated good linearity in the range of 0.1–30 μg/mL (r > 0.99), and the lower limit of quantification was 0.1 μg/mL. Moreover, the intra- and inter-day precision relative standard deviation of FLC was less than 9.09% and 6.51%, respectively. There were no significant differences in the pharmacokinetic parameters between the two groups. Conclusion The results showed that DHM administration did not significantly alter FLC pharmacokinetics in SD rat plasma.

show abstract